Skip to main content
logo
Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
13.47
-0.29 (-2.11%)
Oct 16, 2026, 4:00 PM EDT - Market closed

Jade Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-153.24-127.41-93.96
Depreciation & Amortization
0.040.03-
Loss (Gain) From Sale of Investments
-1.64-0.78-
Stock-Based Compensation
34.720.012.51
Other Operating Activities
0.0621.6725.2
Change in Accounts Payable
-0.150.362.58
Change in Other Net Operating Assets
-3.29-8.5618.44
Operating Cash Flow
-123.51-94.69-45.23
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-0.06-0.2-
Investment in Securities
-352.88-246.78-
Other Investing Activities
-0.03-0.03-
Investing Cash Flow
-352.97-247.01-

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Total Debt Issued
-205-190
Net Debt Issued (Repaid)
-205-190
Issuance of Common Stock
578.95385.38-
Other Financing Activities
-11.06-24.62-6
Financing Cash Flow
362.89360.77184

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Foreign Exchange Rate Adjustments
-0.1-0.02-
Net Cash Flow
-113.6919.05138.77

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-123.57-94.89-45.23
Free Cash Flow Growth
---
Free Cash Flow Per Share
-2.33-3.03-14.33
Levered Free Cash Flow
--61.35-
Unlevered Free Cash Flow
--59.1-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
-3.44-8.221.02
SEC Filings: 10-K · 10-Q